Abstract
The high toxicity of most anticancer chemotherapeutic drugs and their deactivation by multidrug resistant phenotypes motivated an extensive search for drugs with new modes of action. Host defense peptides (HDPs) represent a promising class of natural-source drugs with a distinct mode of action, decreased likelihood of resistance development, and low intrinsic cytotoxicity. However, the development of antitumoral HDP-based compounds has been hindered by poor understanding of the molecular mechanisms of the HDPs’ selective killing of cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
